Advice
Following a full submission
atazanavir (Reyataz) is accepted for use within NHS Scotland in antiretroviral treatment naïve HIV-1 infected adults in combination with other antiretroviral medicinal products.
The combination of atazanavir and ritonavir was non-inferior to a standard boosted protease inhibitor regimen in treatment naïve HIV patients. The combined regimen was associated with lower incidences of diarrhoea and lipid adverse-effects and a higher incidence of hyperbilirubinaemia in this patient population.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- atazanavir (Reyataz)
- SMC ID:
- 520/08
- Indication:
- HIV-1 infected adults
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 December 2008